| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.51(B) |
| Last
Volume: |
1,754,233 |
Avg
Vol: |
4,315,920 |
| 52
Week Range: |
$4.13 - $8.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 1115 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
183,601 |
183,601 |
183,601 |
| Total Buy Value |
$0 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
| Total People Bought |
0 |
10 |
10 |
10 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
0 |
11,387 |
11,387 |
506,586 |
| Total Sell Value |
$0 |
$69,059 |
$69,059 |
$6,068,300 |
| Total People Sold |
0 |
2 |
2 |
10 |
| Total Sell Transactions |
0 |
2 |
2 |
16 |
| End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bennett J Claude |
President |
• • – |
2007-02-26 |
4 |
OE |
$1.18 |
$95,278 |
D/D |
16,171 |
65,730 |
|
- |
|
| Nugent Jonathan M |
VP Corp Communications |
• – – |
2007-01-31 |
4 |
B |
$8.64 |
$1,928 |
D/D |
223 |
223 |
2.66 |
- |
|
| Riggs Randall B |
Senior VP Business Development |
• – – |
2007-01-31 |
4 |
B |
$8.64 |
$10,235 |
D/D |
1,184 |
1,928 |
2.74 |
- |
|
| Stonehouse Jon P |
CEO |
• • – |
2007-01-09 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Spencer William M III |
Director |
– • – |
2006-12-27 |
4 |
D |
$11.81 |
$12 |
D/D |
(1) |
186,761 |
|
- |
|
| Nugent Jonathan M |
VP Corp Communications |
• – – |
2006-09-01 |
4 |
AS |
$10.15 |
$57,088 |
D/D |
(5,600) |
0 |
|
- |
|
| Nugent Jonathan M |
VP Corp Communications |
• – – |
2006-09-01 |
4 |
OE |
$4.66 |
$26,096 |
D/D |
5,600 |
5,600 |
|
- |
|
| Featheringill William W |
Director |
– • – |
2006-08-29 |
4 |
GD |
$9.89 |
$593,400 |
D/D |
60,000 |
1,797,572 |
|
- |
|
| Alexander W James |
SR. VP, Chief Medical Officer |
• – – |
2006-08-14 |
4 |
B |
$9.00 |
$11,565 |
D/D |
1,285 |
1,285 |
2.74 |
- |
|
| Riggs Randall B |
Senior VP Business Development |
• – – |
2006-07-31 |
4 |
B |
$9.69 |
$7,209 |
D/D |
744 |
744 |
2.74 |
- |
|
| Bennett J Claude |
President |
• • – |
2006-05-10 |
4 |
B |
$6.50 |
$42,660 |
D/D |
6,563 |
49,559 |
2.81 |
- |
|
| Bennett J Claude |
President |
• • – |
2006-05-03 |
4 |
S |
$15.07 |
$397,134 |
D/D |
(26,243) |
42,996 |
|
- |
|
| Bennett J Claude |
President |
• • – |
2006-05-03 |
4 |
B |
$6.50 |
$227,500 |
D/D |
35,000 |
69,239 |
2.81 |
- |
|
| Seidenberg Beth C |
Director |
– • – |
2006-05-03 |
4 |
B |
$15.21 |
$46,030 |
I/I |
3,000 |
3,000 |
2.1 |
- |
|
| Bennett J Claude |
President |
• • – |
2006-04-03 |
4 |
AS |
$18.00 |
$180,249 |
D/D |
(10,000) |
34,239 |
|
- |
|
| Bennett J Claude |
President |
• • – |
2006-04-03 |
4 |
OE |
$16.38 |
$174,951 |
D/D |
10,684 |
44,239 |
|
- |
|
| Darwin Michael A |
Chief Financial Officer |
• – – |
2006-03-15 |
4 |
GD |
$21.00 |
$14,028 |
D/D |
668 |
0 |
|
- |
|
| Darwin Michael A |
Chief Financial Officer |
• – – |
2006-03-15 |
4 |
AS |
$19.00 |
$435,176 |
D/D |
(22,650) |
668 |
|
- |
|
| Darwin Michael A |
Chief Financial Officer |
• – – |
2006-03-15 |
4 |
OE |
$0.87 |
$65,890 |
D/D |
22,650 |
23,318 |
|
- |
|
| Bugg Charles E |
Chairman |
• • – |
2006-03-03 |
4 |
AS |
$20.28 |
$1,032,241 |
D/D |
(50,000) |
62,439 |
|
- |
|
| Bugg Charles E |
Chairman |
• • – |
2006-03-03 |
4 |
OE |
$1.04 |
$724,244 |
D/D |
54,882 |
112,439 |
|
- |
|
| Bennett J Claude |
President |
• • – |
2006-03-03 |
4 |
AS |
$20.93 |
$209,973 |
D/D |
(10,000) |
33,555 |
|
- |
|
| Bennett J Claude |
President |
• • – |
2006-03-03 |
4 |
OE |
$16.38 |
$189,131 |
D/D |
11,550 |
43,555 |
|
- |
|
| Riggs Randall B |
Senior VP Business Development |
• – – |
2006-03-03 |
4 |
S |
$20.35 |
$30,819 |
D/D |
(1,512) |
0 |
|
- |
|
| Bennett J Claude |
President |
• • – |
2006-02-13 |
4 |
S |
$16.92 |
$50,826 |
D/D |
(3,000) |
32,005 |
|
- |
|
755 Records found
|
|
Page 29 of 31 |
|
|
